Patents by Inventor Petteri Rummakko

Petteri Rummakko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20240124431
    Abstract: The present invention relates to compounds of formula (I), wherein A is a 3-10 membered carbocyclyl or a 4-12 membered heterocyclyl containing 1-4 heteroatoms selected from O, N, or S; B is any of the following groups (1), (2), or (3); C is any of the following groups (1?), (2?), (3?), or (4?); G1 is CH2, NH, or O; G2 and G3 are, independently, CH or N; Z is —C(O)—, —SO2—, —C1-3 alkyl-, or —CH2—C(O)—; L is a bond, —C1-7 alkyl-, or —C1-7 alkenyl-. The compounds of formula (I) are cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, for example, androgen receptor or estrogen receptor, dependent diseases and conditions, such as cancer including prostate cancer and estrogen cancer.
    Type: Application
    Filed: November 30, 2021
    Publication date: April 18, 2024
    Inventors: David DIN BELLE, Pekka PIETIKÄINEN, Petteri RUMMAKKO, Gerd WOHLFAHRT
  • PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS
    Publication number: 20210347765
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 11, 2021
    Inventors: David DIN BELLE, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors
    Patent number: 11098032
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: August 24, 2021
    Assignee: ORION CORPORATION
    Inventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS
    Publication number: 20200299280
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: David DIN BELLE, Mikko MÄKELÄ, Mikko PASSINIEMI, Pekka PIETIKÄINEN, Petteri RUMMAKKO, Eija TIAINEN, Matti VAISMAA, Gerd WOHLFAHRT
  • Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors
    Patent number: 10717726
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 21, 2020
    Assignee: ORION CORPORATION
    Inventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS
    Publication number: 20190359601
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 28, 2019
    Inventors: David DIN BELLE, Mikko MÄKELÄ, Mikko PASSINIEMI, Pekka PIETIKÄINEN, Petteri RUMMAKKO, Eija TIAINEN, Matti VAISMAA, Gerd WOHLFAHRT
  • CYP17 inhibitors/antiandrogens
    Patent number: 9890139
    Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: February 13, 2018
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Petteri Rummakko, Arja Karjalainen, Mikko Passiniemi, Pekka Pietikäinen, Anssi Haikarainen, Emilia Väisänen, Eija Tiainen
  • NOVEL CYP17 INHIBITORS/ANTIANDROGENS
    Publication number: 20160130254
    Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 12, 2016
    Inventors: Gerd WOHLFAHRT, Petteri RUMMAKKO, Arja KARJALAINEN, Mikko PASSINIEMI, Pekka PIETIKÄINEN, Anssi HAIKARAINEN, Emilia VÄISÄNEN, Eija TIAINEN
  • 2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
    Patent number: 8809536
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: August 19, 2014
    Assignee: Orion Corporation
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
    Publication number: 20140179926
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Application
    Filed: February 27, 2014
    Publication date: June 26, 2014
    Applicant: ORION CORPORATION
    Inventors: David DIN BELLE, Patrik HOLM, Arto KARLJALAINEN, Arto TOLVANEN, Gerd WOHLFAHRT, Petteri RUMMAKKO
  • 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
    Patent number: 8697723
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: April 15, 2014
    Assignee: Orion Corporation
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
    Publication number: 20130281486
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 24, 2013
    Inventors: David DIN BELLE, Patrik HOLM, Arto KARLJALAINEN, Arto TOLVANEN, Gerd WOHLFAHRT, Petteri RUMMAKKO
  • 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseases
    Patent number: 8492549
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: July 23, 2013
    Assignee: Orion Corporation
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES
    Publication number: 20120035210
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Application
    Filed: July 18, 2008
    Publication date: February 9, 2012
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • Quetiapine hemifumarate purification by crystallization
    Patent number: 8044039
    Abstract: The present invention relates to a process for preparing and purifying crystalline quetiapine hemifumarate, which comprises preparing crystalline quetiapine hemifumarate via a crystalline salt, which is not a salt of fumaric acid.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: October 25, 2011
    Assignee: Fermion Oy
    Inventors: Arne Grumann, Soini Huhta, Petteri Rummakko, Viesturs Lusis
  • Crystallization process of quetiapine hemifumarate
    Patent number: 8044038
    Abstract: The present invention relates to a process for preparing crystalline quetiapine hemifumarate, which comprises crystallizing or re-crystallizing quetiapine hemifumarate from a mixture of water and a water soluble alcohol.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: October 25, 2011
    Assignee: Fermion Oy
    Inventors: Petteri Rummakko, Arne Grumann, Soini Huhta, Tuomas Koiranen
  • Preparation of quetiapine
    Patent number: 7863441
    Abstract: The present invention discloses a process for the preparation of quetiapine, which comprises the ring closure of a compound of the formula shown below, as well as novel intermediates in the process.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: January 4, 2011
    Assignee: Fermion Oy
    Inventors: Petteri Rummakko, Soini Huhta, Arne Grumann
  • Preparation method for quetiapine
    Patent number: 7858777
    Abstract: The present invention discloses a process for the preparation of quetiapine, which comprises the ring closure and deprotection of a compound of the formula (I), as well as novel intermediates in the process.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: December 28, 2010
    Assignee: Fermion Oy
    Inventors: Leif Hilden, Arne Grumann, Soini Huhta, Petteri Rummakko
  • 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES
    Publication number: 20100216836
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Application
    Filed: July 18, 2008
    Publication date: August 26, 2010
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • Quetiapine Hemifumarate Purification by Crystallization
    Publication number: 20090156802
    Abstract: The present invention relates to a process for preparing and purifying crystalline quetiapine hemifumarate, which comprises preparing crystalline quetiapine hemifumarate via a crystalline salt, which is not a salt of fumaric acid.
    Type: Application
    Filed: October 26, 2006
    Publication date: June 18, 2009
    Applicant: FERMION OY
    Inventors: Arme Grumann, Soini Huhta, Petteri Rummakko, Viesturs Lusis